Longevity / mitochondrial interest
Epitalon vs Elamipretide
Elamipretide has multiple modern controlled human trials and a narrow disease-specific regulatory pathway; Epitalon longevity claims rely on older regional.
At a glance
Epitalon
Elamipretide
Human evidence
Older regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified.
Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use.
Research focus
Ageing biology, telomere research, retinal research
Mitochondrial disease; Barth syndrome; broader mitochondrial research
Regulatory status
Not FDA-approved; compounded-use safety information is insufficient.
Forzinity (elamipretide) received FDA accelerated approval for Barth syndrome patients ≥30 kg; this does not make generic SS-31 vials approved.
Route / formulation
Do not confuse Epitalon (tetrapeptide) with Epithalamin (pineal extract) when citing older literature.
Generic SS31 research products are not equivalent to Forzinity and may differ in quality/formulation.
Not therapeutically equivalent Elamipretide has multiple modern controlled human trials and a narrow disease-specific regulatory pathway; Epitalon longevity claims rely on older regional and preclinical/cell evidence.